PT  - JOURNAL ARTICLE
AU  - York, Elizabeth N.
AU  - Meijboom, Rozanna
AU  - Thrippleton, Michael J.
AU  - Bastin, Mark E.
AU  - Kampaite, Agniete
AU  - White, Nicole
AU  - Chandran, Siddharthan
AU  - Waldman, Adam D.
AU  - ,
TI  - Longitudinal microstructural MRI markers of demyelination and neurodegeneration in early relapsing-remitting multiple sclerosis: magnetisation transfer, water diffusion and g-ratio
AID  - 10.1101/2022.06.08.22276139
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.08.22276139
4099  - http://medrxiv.org/content/early/2022/07/22/2022.06.08.22276139.short
4100  - http://medrxiv.org/content/early/2022/07/22/2022.06.08.22276139.full
AB  - Introduction Quantitative microstructural MRI, such as myelin-sensitive magnetisation transfer ratio (MTR) or saturation (MTsat), axon-sensitive water diffusion Neurite Orientation Dispersion and Density Imaging (NODDI), and the derived aggregate g-ratio, may provide more specific markers of white matter integrity than conventional MRI for early patient stratification in relapsing-remitting multiple sclerosis (RRMS). The aim of this study is to determine the sensitivity of such markers to longitudinal pathological change within cerebral white matter lesions (WML) and normal-appearing white matter (NAWM) in recently diagnosed RRMS.Methods Seventy-nine people with recently diagnosed RRMS, from the FutureMS longitudinal cohort, were recruited to an extended MRI protocol at baseline and one year later. Twelve healthy volunteers received the same MRI protocol, repeated within two weeks. Ethics approval and written informed consent were obtained.3T MRI included magnetisation transfer, and multi-shell diffusion-weighted imaging. NAWM and whole brain volume (WBV) were segmented from 3D T1-weighted MPRAGE, and WML from T2-weighted FLAIR. MTR, MTsat, NODDI isotropic (ISOVF) and intracellular (ICVF) volume fractions, and aggregate g-ratio were measured within WML and NAWM. G-ratio was calculated from MTsat and NODDI data.Longitudinal change in brain volume and microstructural metrics was assessed with paired t-tests (α=0.05) and linear mixed models, corrected for confounding factors and multiple comparisons. Longitudinal changes were compared with test-retest Bland-Altman limits of agreement from healthy volunteer control white matter. The influence of varying MTsat and NODDI parameters on derived g-ratio was explored in silico.Results In NAWM, paired t-tests show a significant increase in g-ratio (p=0.012) and ICVF (p=0.025), and a decrease in MTsat (p=0.033) over one year, but no change in MTR, or ISOVF. Linear mixed models show effects in NAWM remain significant after adjusting for covariates and after False Discovery Rate (FDR) correction for multiple comparisons, and no significant change in WBV. In WML, MTsat and NODDI metrics increase significantly over one year (linear mixed models, FDR-corrected p<0.05). In silico simulations show that increase in g-ratio may result from a decrease in MTsat or ISOVF, or an increase in ICVF.Discussion G-ratio and MTsat changes in NAWM over one year indicate subtle myelin loss in early RRMS, which were not apparent with NAWM MTR or in WBV. Increases in NAWM and WML NODDI ICVF were not anticipated, and raise the possibility of axonal swelling or morphological change. Increases in WML MTsat may reflect myelin repair. Changes in NODDI ISOVF are more likely to reflect alterations in water content. Competing MTsat and ICVF changes may account for the absence of g-ratio change in WML. Longitudinal changes in microstructural measures are significant at a group level, however detection in individual patients in early RRMS is limited by technique reproducibility.Conclusion MTsat and g-ratio are more sensitive than MTR to early pathological changes in RRMS, but complex dependence of g-ratio on NODDI parameters limit the interpretation of aggregate measures in isolation. Improvements in technique reproducibility and validation of MRI biophysical models across a range of pathological tissue states are needed.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://wellcomeopenresearch.org/articles/7-94/v1 Funding StatementENY was supported by a Chief Scientist Office SPRINT MND/MS Studentship and funding from the Anne Rowling Regenerative Neurology Clinic, Edinburgh. MJT is funded by the NHS Lothian Research and Development Office. RM and AK are funded by the UK MS Society Edinburgh Centre for MS Research grant (grant reference 133). FutureMS, hosted by Precision Medicine Scotland Innovation Centre (PMS-IC), was funded by a grant from the Scottish Funding Council to PMS-IC and Biogen Idec Ltd Insurance. Additional funding for the University of Edinburgh 3T MRI Research scanner in Royal Infirmary Edinburgh is funded by Wellcome (104916), Dunhill Trust (R380R/1114), Edinburgh and Lothians Health Foundation (2012/17), Muir Maxwell Research Fund, Edinburgh Imaging, and University of Edinburgh.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The South East Scotland Research Ethics Committee 02 of the National Health Service (NHS, United Kingdom) gave ethical approval for this work under reference 15/SS/023.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData requests from a third party will be handled on a case by case basis by the steering committee and data custodians.CNSCentral nervous systemdMRIDiffusion-weighted magnetic resonance imagingDMTsDisease-modifying therapiesEDSSExpanded Disability Status ScaleFLAIRFluid-Attenuated Inversion RecoveryFLASHFast Low-Angle ShotICVF(NODDI-derived) intraneurite signal fractionihMTRInhomogeneous magnetisation transfer ratioISOVF(NODDI-derived) isotropic signal fractionMRIMagnetic resonance imagingMSMultiple sclerosisMTIMagnetisation transfer imagingMTRMagnetisation transfer ratioMTsatMagnetisation transfer saturationNAWM‘Normal-appearing’ white matterNODDINeurite Orientation Dispersion and Density ImagingODI(NODDI-derived) orientation dispersion indexRRMSRelapsing-remitting multiple sclerosisSNRSignal-to-noiseSPMSSecondary progressive multiple sclerosisWMLWhite matter lesions